Download PDF
Arzneimittelforschung 2002; 52(4): 251-255
DOI: 10.1055/s-0031-1299888
Lipid Reducers
Editio Cantor Verlag Aulendorf (Germany)

Clinical Efficacy of Pitavastatin, a New 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase Inhibitor, in Patients with Hyperlipidemia

Dose-finding study using the double-blind, three-group parallel comparison
Yasushi Saito
a   The Second Department of Internal Medicine, School of Medicine, Chiba University, Chiba, Japan
,
Nobuhiro Yamada
b   Institute of Clinical Medicine, School of Medicine, Tsukuba University, Tsukuba, Japan
,
Tamio Teramoto
c   Department of Internal Medicine, School of Medicine, Teikyo University, Tokyo, Japan
,
Hiroshige Itakura
d   The National Health and Nutrition Research Laboratory, Tokyo, Japan
,
Yoshiya Hata
e   School of Medicine, Kyorin University, Tokyo, Japan
,
Noriaki Nakaya
f   Fussa National Health Insurance Hospital, Fussa, Japan
,
Hiroshi Mabuchi
g   The Second Department of Internal Medicine, School of Medicine, Kanazawa University, Kanazawa, Japan
,
Motoo Tushima
h   Department of Arteriosclerotic and Metabolic Medicine, National Cardiovascular Disease Center, Osaka, Japan
,
Jun Sasaki
i   The Second Department of Internal Medicine, School of Medicine, Fukuoka University, Fukuoka, Japan
,
Yuichiro Goto
j   School of Medicine, Tokai University, Isehara, Japan
,
Nobuya Ogawa
k   School of Medicine, Ehime University, Matsuyama, Japan
› Author Affiliations
Further Information

Publication History

Publication Date:
26 December 2011 (online)

  PDF Download  Permissions and Reprints

Summary

Pitavastatin (CAS 147526-32-7, NK-104), the first totally synthetic 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor discovered in Japan, was examined. Pitavastatin significantly decreased the serum levels of total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) at doses of 1 mg/day or more, and significant dose-dependence of the effect of this drug was observed within the dose range from 1 mg/ day to 4 mg/day. It also significantly decreased the serum levels of triglycerides (TG) within this dose range. There was no dose-dependence of the incidence of adverse reactions to pitavastatin.

Zusammenfassung

Klinische Wirksamkeit von Pltavastatin, einem neuen 3-Hydroxy-3-Methylglutaryl-Coenzym A-Reduktase-Inhibitor, bei Patienten mit Hyperlipidämie / Doppelblinde Dosisfindungsstudie mit Drei-Gruppen-Parallelvergleich

Pitavastatin(CAS 147526-32-7, NK-104), der erste, vollständig synthetische 3-Hydroxy-3-Methylglutaryl-Coenzym A (HMG-CoA)-Reduktase-Inhibitor, der in Japan entdeckt wurde, wurde untersucht. Pitavastatin senkte signifikant die Serumkonzentration von Gesamt- und LDL-Cholesterin (LDL: low density lipoprotein) bei einer Dosierung von 1 mg/Tag oder mehr. Signifikante, dosisabhängige Arzneimitteleffekte wurden innerhalb eines Dosisbereichs von 1–4 mg/Tag beobachtet. Außerdem wuden die Triglyzerid (TG) Serum konzentrationen innerhalb dieses Dosisbereichs signifikant gesenkt. Eine Dosisabhängigkeit in bezug auf die Häufigkeit Pitavastatin-induzierter Nebenwirkungen wurde nicht beobachtet.

Key words

CAS 147526-32-7 - HMG-CoA reductase inhibitor - Hyperlipidemia - NK-104 - Pitavastatin, dose-finding study, effects on total cholesterol and LDL cholesterol